BIONIKK
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- NCT02960906 ↗
- Completed
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- Deep
We haven't built an HCP commentary report on BIONIKK (nivolumab plus ipilimumab; nivolumab; pazopanib in first-line metastatic clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from all 27 indexed sources (Sep 2018 – Oct 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether molecular profiling can guide treatment choice
- Which molecular signatures may distinguish benefit from immunotherapy versus VEGF-targeted therapy
- Whether biomarker-guided treatment can be validated and implemented in routine practice
Also discussed: second-line treatment, IMDC criteria.
Indexed commentary on BIONIKK so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 19 | |
| YouTube | 4 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Clear Cell Metastatic Renal Cell Carcinoma
- Interventions
- Nivolumab; Ipilimumab; Pazopanib; Sunitinib
- Arms
- ccRCC molecular subgroup 1: 1A · Experimental
- ccRCC molecular subgroup 1: 1B · Experimental
- ccRCC molecular subgroup 4: 4A · Experimental
- ccRCC molecular subgroup 4: 4B · Experimental
- ccRCC molecular subgroup 2: 2C · Experimental
- ccRCC molecular subgroup 2: 2B · Experimental
- ccRCC molecular subgroup 3: 3B · Experimental
- ccRCC molecular subgroup 3: 3C · Experimental
- Enrollment
- 200
- Primary outcomes
- ORR evaluation according to molecular groups (ccRCC1 to 4) and assigned treatment
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- Start
- May 31, 2017
- Primary completion
- Feb 15, 2021
- Results posted
- No
- Registry record
- NCT02960906 · updated Apr 26, 2021
Publications
linked from the registry- Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, Elaidi RT, Verkarre V, Sun CM, Chevreau C, Bennamoun M, Lang H, Tricard T, Fridman WH, Sautes-Fridman C, Su X, Plassard D, Keime C, Thibault-Carpentier C, Barthelemy P, Oudard SM, Davidson I, Malouf GG. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma. Cancer Res. 2023 Sep 1;83(17):2952-2969. doi: 10.1158/0008-5472.CAN-22-3034. PubMed 37335139
- Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthelemy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Mejean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouin A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautes-Fridman C, Oudard S. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. PubMed 35390339
- Epaillard N, Simonaggio A, Elaidi R, Azzouz F, Braychenko E, Thibault C, Sun CM, Moreira M, Oudard S, Vano YA. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naive metastatic kidney cancer. Bull Cancer. 2020 Jun;107(5S):eS22-eS27. doi: 10.1016/S0007-4551(20)30283-6. PubMed 32620212